Cytokinetics granted European Orphan designation for reldesemtiv for treatment of SMA
Cytokinetics announced the EMA has granted orphan medicinal product designation to reldesemtiv for potential treatment of spinal muscular atrophy. The FDA previously granted orphan drug designation to reldesemtiv for the potential treatment of SMA in 2017. July 23, 2019